• 1
    Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 20062012.
  • 2
    Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 23262333.
  • 3
    Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 21292134.
  • 4
    Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747752.
  • 5
    Seron D, Moreso F, Fulladosa X et al. Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727733.
  • 6
    Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 2228.
  • 7
    Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953961.
  • 8
    Seron D, Moreso F, Ramon JM et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplant 2000; 69: 18491855.
  • 9
    Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 17761785.
  • 10
    Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770781.
  • 11
    Cosio FG, Grande JP, Wadei H et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 24642472.
  • 12
    Gloor JM, Cosio FG, Rea DJ et al. Histologic findings one year after positive crossmatch or ABO incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 18411847.
  • 13
    Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411422.
  • 14
    Schwarz A, Mengel M, Gwinner W et al. Risk factors for chronic allograft nephropathy after renal transplantation: A protocol biopsy study. Kidney Int 2005; 67: 341348.
  • 15
    Mengel M, Gwinner W, Schwarz A et al. Infiltrates in protocol biopsies from renal allografts. Am J Transplant 2006, In press 356365.
  • 16
    Mihatsch MJ, Gudat F, Ryffel B, Thiel G. In: TisherCC, BrennerBM, eds. Cyclosporine nephropathy, in renal pathology: With clinical and functional correlations, Philadelphia : J.B. Lippincott, 1994: 16411681.
  • 17
    Sis B, Dadras F, Khoshjou F et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant 2006; 6: 14441450.
  • 18
    Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP project. Kidney Int 2001; 60: 19982012.
  • 19
    Roberts IS, Brenchley PE. Mast cells: The forgotten cells of renal fibrosis. J Clin Pathol 2000; 53: 858862.
  • 20
    Schwarz A, Gwinner W, Hiss M et al. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005; 5: 19921996.
  • 21
    Furness PN, Philpott CM, Chorbadjian MT et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplant 2003; 76: 969973.
  • 22
    Einecke G, Fairhead T, Hidalgo LG et al. Tubulitis and epithelial cell alterations in mouse kidney transplant rejection are independent of CD103, perforin or granzymes A/B. Am J Transplant 2006; 6: 21092120.
  • 23
    Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplant 2002; 74: 916923.
  • 24
    Hoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573581.
  • 25
    Ishii Y, Sawada T, Kubota K et al. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 2005; 67: 321332.
  • 26
    Woywodt A, Schroeder M, Mengel M et al. Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage. Hypertension 2003; 41: 720723.